Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes

Overview

Purpose is to identify whether immune markerscan predict success of salvage anti-retroviral therapy.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective

Detailed Description

Over the last several years two markers of disease have been utilized to determine if antiretroviral therapy has been successful, one is a CD4 cell count (reflects the immunocompetence of an infected individual) and a HIV viral load (a blood test used to determine the amount of HIV in the infected individual). However in patients who fail their first line of therapythe likelihood of extended resuppressing viral replication with subsequent therapies may be as low as 25-50%. This information may take several months to determine the new therapies possible continuing success. It would be preferable to have additional markers that respond to therapies in the first several weeks to such therapies, therfore possibly offering patients alternate treatment earlier without potentiatinglong term side effects and possible further drug resistance.

Participating in This Clinical Trial

Inclusion Criteria

  • Patient must be HIV infected – must be ≥18 years old – must have been taking the same combination ARV regimen (≥3 drugs) for at least 3 months. – Must be experiencing virologic failure (viral load ≥50 copies/mL on two occasions at least 2 weeks apart). – must be changed to a salvage antiretroviral regimen – Patient has to have signed and dated a full infomred consent. Exclusion Criteria:

  • Patient with any of the following abnormal laboratory test results in the previous 3 months: – Hemaglobin <100 g/L – Platelet count <20,000 cells/L – INR ≥3.5 IU – PTT ≥60 IU – Patient with other significant underlying disease (non-HIV) that might impact immune markers ( eg. advanced liver disease, malignancy).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ottawa Hospital Research Institute
  • Collaborator
    • Ontario HIV Treatment Network
  • Overall Official(s)
    • J Angel, MD, Principal Investigator, Ottawa Hospital Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.